Table 2. Comparisons included in trials with triple therapy.

Intervention	Trials	Durationc	N	HbA1c	BW	AE	SAE	HypoG	Definition of hypoglycaemia
MET+ SU vs MET+ SU+ DPP-4-i	Hermansen et al. (2007) a	24	441	x	x	x	x	x	ND
	Owens et al. (2011)	24	1,055	x	x	x	x	x	ND
	Lukashevich et al. (2014)	24	318	x	x	x	x	x	Symptoms suggestive of hypoglycaemia and a self-monitored plasma glucose measurement <3.1 mmol/l
MET + SU + TZD	Moses et al. (2014)	24	257	x	x	x	x	x	Symptomatic hypoglycaemia ± glucose measurement
	Dailey et al. (2004)	24	365	x	x	x		x	Symptomatic episodes with an associated fingerstick blood glucose ≤ 50 mg/dL
MET + SU + GLP-1-RA	Kendall et al. (2005)	30	733	x	x	x	x	x	Symptoms consistent with hypoglycaemia ± a documented plasma glucose concentration of <3.33 mmol/l
MET+ SU+ SGLT2-i	Russell-Jones et al. (2009) b	26	581	x	x	x	x	x	Plasma glucose of <56 mg/dL (3.1 mmol/l)
	Wilding et al. (2013)	52	469	x	x	x	x	x	Symptomatic episodes with an associated fingerstick or plasma glucose ≤ 3.9 mmol/l
MET+ SU+ INS	Russell-Jones et al. (2009) b	26	581	x	x	x	x	x	Plasma glucose of <56 mg/dL (3.1 mmol/l)
SU+ DPP-4-i	a Hermansen et al. (2007)	24	441	x	x	x	x	x	ND
MET+ SU+ INS vs MET+ SU+ GLP-1-RA	Russell-Jones et al. (2009) b	26	581	x	x	x	x	x	Plasma glucose of <56 mg/dL (3.1 mmol/L)
	Bergenstal et al. (2009)	24	372	x	x	x	x	x	Plasma glucose of <56 mg/dL (3.1 mmol/L)
	Heine et al. (2005)	26	549	x	x	x		x	Plasma glucose of <56 mg/dL (3.1 mmol/L)
	Nauck et al. (2007)	52	501	x	x	x	x	x	Any time a patient experienced a sign or symptom of hypoglycaemia or noted a blood glucose level <60 mg/dL (3.4 mmol/L).
MET+ SU+ TZD	Rosenstock et al. (2006)	24	216	x	x	x	x	x	Event with clinical symptoms consistent with hypoglycaemia, confirmed with a meter reading.
MET+ TZD+ DPP-4-i vs
MET+ TZD	Bosi et al. (2011)	52	803	x	x	x	x	x	Blood glucose of <3.33 mmol/L with symptoms, or <2.78 mmol/L regardless of symptoms
	DeFronzo et al. (2012)	26	1,554	x		x	x	x
MET+ SU+ TZD	Derosa et al. (2013)	52	453	x	x				NR
MET+ SU+ DPP-4-i vs MET+ SU+ SGLT2-i	Schernthaner et al. (2013)	52	755	x	x	x	x	x	Symptomatic episodes with fingerstick glucose ≤ 3.9 mmol/l
MET+ SU+ TZD	Liu et al. (2013)	24	119	x	x	x	x	x	ND

Notes.

AE

adverse event

BW

body weight

DPP-4-i

dipeptidyl peptidase-4 inhibitor

GLP-1-RA

glucagon-like peptide-1 receptor agonist

HbA_1c

glycated haemoglobin

HypoG

hypoglycaemic event

INS

insulin

MET

metformin

ND

not defined

NR

not reported

SAE

serious adverse event

SGLT2-i

sodium glucose co-transporter 2 inhibitor

SU

sulfonylurea

TZD

thiazolidinedione

^aOne trial included three treatment arms (MET+ SU+ DPP4-i, MET+ SU and SU+ DPP4-i) and provided information for those comparisons.

^bOne trial included three treatment arms (MET+ SU+ GLP-1-RA, MET+ SU and MET+ SU+ INS) and provided information for those comparisons.

^cDuration in months.